MannKind Corporation (MNKD) saw its stock plummet by 5.19% in pre-market trading on Thursday, despite reporting strong revenue growth and progress across its pipeline in the fourth quarter of 2024. The company's Q4 earnings failed to enthuse investors, who seemingly adopted a cautious stance ahead of several key upcoming catalysts.
The biopharmaceutical firm recorded revenues of $286 million for the full year 2024, a 43% increase over the prior year, driven by robust growth in royalties and manufacturing revenue from its partnership with United Therapeutics for Tyvaso DPI. Afrezza, MannKind's flagship product for diabetes, also witnessed a 17% year-over-year increase in sales.
MannKind's management expressed optimism surrounding several potential catalysts in the near future, including the anticipated approval of Afrezza for the pediatric market in 2026, which could significantly boost the product's sales. The company is also progressing its clofazimine and nintedanib clinical programs, with interim analysis and FDA meetings slated for 2025 and 2026. Positive readouts from United Therapeutics' TETON trials evaluating Tyvaso DPI in IPF could further propel MannKind's fortunes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。